N-Acetyl-L-tryptophan-d3

N-Acetyl-L-tryptophan-d3 is the deuterium labeled N-Acetyl-L-tryptophan (HY-W011978) . N-Acetyl-L-tryptophan is an antagonist of the neurokinin-1 receptor (NK-1R), disrupting the binding of substance P (SP) to NK-1R. This action provides neuroprotective effects, improving memory deficits and motor impairments. N-Acetyl-L-tryptophan is also an inhibitor of cytochrome c (Cytochrome c), and it exerts antioxidant and anti-inflammatory effects by inhibiting the expression of IL-1β and the activation of caspase-1. N-Acetyl-L-tryptophan holds promise for research in neurodegenerative and inflammatory diseases[1][2][3][4].

Product Specifications

UNSPSC

12352005

Target

Caspase; Endogenous Metabolite; Interleukin Related; Isotope-Labeled Compounds; Mitochondrial Metabolism; Neurokinin Receptor

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Field of Research

Inflammation/Immunology; Neurological Disease

Smiles

O=C(O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C([2H])([2H])[2H])=O

Molecular Formula

C13H11D3N2O3

Molecular Weight

249.28

References & Citations

[1]Sirianni A C, et al. N‐acetyl‐l‐tryptophan, but not N‐acetyl‐d‐tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis[J]. Journal of Neurochemistry, 2015, 134 (5) : 956-968.|[2]Li H, et al. Inhibition of excessive mitophagy by N-acetyl-L-tryptophan confers hepatoprotection against Ischemia-Reperfusion injury in rats[J]. PeerJ, 2020, 8: e8665. |[3]Thornton E, et al. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model[J]. Parkinsonism & related disorders, 2014, 20 (5) : 508-513. |[4]Fernandes J, et al. N-acetyl-L-tryptophan, a substance-P receptor antagonist attenuates aluminum-induced spatial memory deficit in rats[J]. Toxicology Mechanisms and Methods, 2018, 28 (5) : 328-334.